Bovi-Shield 4This page contains information on Bovi-Shield 4 for veterinary use.
The information provided typically includes the following:
- Bovi-Shield 4 Indications
- Warnings and cautions for Bovi-Shield 4
- Direction and dosage information for Bovi-Shield 4
Bovi-Shield 4This treatment applies to the following species:
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine
Modified Live Virus
PRODUCT DESCRIPTION: Bovi-Shield 4 is for vaccination of healthy, nonpregnant cattle as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus, bovine viral diarrhea (Type 1 and Type 2) caused by bovine viral diarrhea (BVD) virus, and disease caused by parainfluenza3 (PI3) virus and bovine respiratory syncytial virus (BRSV). Bovi-Shield 4 may be administered to calves nursing pregnant cows provided their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD® FP® or PregGuard® GOLD FP vaccine prior to breeding. Bovi-Shield 4 is a freeze-dried preparation of modified live virus (MLV) strains of IBR, BVD Type 1, PI3, and BRSV viruses, plus a sterile diluent used to rehydrate the freeze-dried vaccine. Viral antigens are propagated on established cell lines. To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP or PregGuard GOLD FP product with the second dose administered approximately 30 days prebreeding.
DISEASE DESCRIPTION: IBR, BVD, PI3, and BRSV viruses are commonly associated with respiratory disease and/or reproductive failure in cattle. IBR virus infection is characterized by high temperature, excessive nasal discharge, conjunctivitis and ocular discharge, inflamed nose (“red nose”), increased rate of respiration, coughing, loss of appetite, and depression. Cattle infected during pregnancy may abort.
BVD virus may be transmitted in nasal secretions, saliva, blood, feces, and/or urine, and by direct contact with contaminated objects; it invades through the nose and mouth and replicates systemically. Infection during pregnancy may result in abortion, fetal resorption, or congenital malformation of the fetus. Moreover, if susceptible cows are infected with noncytopathic BVD virus during the first trimester of pregnancy, their calves may be born persistently infected with the virus. Exposure of those calves to certain virulent cytopathic BVD virus strains may precipitate BVD-mucosal disease. Clinical signs of BVD include loss of appetite, ulcerations in the mouth, profuse salivation, elevated temperature, diarrhea, dehydration, and lameness.
PI3 virus usually localizes in the upper respiratory tract, causing elevated temperature and moderate nasal and ocular discharge. Although clinical signs typically are mild, PI3 infection weakens respiratory tissues. Invasion and replication of other pathogens, particularly Pasteurella spp., is thereby facilitated and may result in pneumonia.
BRSV is the etiologic agent of a specific viral respiratory disease of cattle of all ages, including nursing calves. Infection is characterized by rapid breathing, coughing, loss of appetite, discharge from the nose and eyes, fever, and swelling around the throat and neck. In an acute outbreak, deaths may follow within 48 hours after onset of signs. Clinically, BRSV infection may be indistinguishable from other viral infections associated with the bovine respiratory disease complex. BRSV infection, like PI3, facilitates invasion and replication of other respiratory pathogens. Exacerbation of clinical signs has been documented when concurrent BRSV and BVD or IBR infection exists.
SAFETY AND EFFICACY: In safety studies of the fractions of Bovi-Shield 4, no adverse reactions to vaccination were observed.
Efficacy of each fraction of Bovi-Shield 4 was demonstrated in challenge-of-immunity studies. Cattle vaccinated with any fraction of Bovi-Shield 4, followed by challenge with a disease-causing strain of that fraction, showed no signs or had significantly fewer clinical signs than nonvaccinated control cattle. Serologic studies demonstrated no immunologic interference among the fractions of Bovi-Shield 4.
Directions For Use
1. General Directions: Vaccination of healthy, nonpregnant cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.
2. Primary Vaccination: Administer a single 2-mL dose to healthy cattle, followed by a second dose of Bovi-Shield BRSV 3-4 weeks later.
3. Revaccination: Annual revaccination with a single dose is recommended.
4. Good animal husbandry and herd health management practices should be employed.
1. Do not use in pregnant cows (abortions can result). Do not use in calves nursing pregnant cows unless their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine prior to breeding.
2. To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP or PregGuard GOLD FP product with the second dose administered approximately 30 days prebreeding.
3. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
4. Use entire contents when first opened.
5. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
6. Burn containers and all unused contents.
7. Do not vaccinate within 21 days before slaughter.
8. Contains gentamicin as preservative.
9. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
10. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 190
Zoetis Inc., Kalamazoo, MI 49007
Presentation: 10 and 50 dose vials.
NAC No.: 36900446
333 PORTAGE STREET, KALAMAZOO, MI, 49007
|Every effort has been made to ensure the accuracy of the Bovi-Shield 4 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2016 North American Compendiums. Updated: 2016-08-21